山东大学临床药理研究所所长、药学院临床药学系主任；山东大学第二医院研究型病房主任、药物临床试验机构副主任；山东省千佛山医院药物临床研究中心主任；创新药临床研究与评价国家药品监督管理局重点实验室常务副主任；山东省儿童药物临床评价与研发工程技术研究中心主任

赵维教授在创新药临床试验与特殊人群个体化治疗研究领域有丰富的临床和科研经验。在Int J Antimicrob Agents, Clin Pharmacol Ther (×3), Clin Pharmacokinet (×9), J Antimicrob Chemother (×9), Antimicrob Agents Chemother (×17)等杂志发表SCI论文150余篇。获得欧盟第七框架、地平线2020，科技部重大新药创制专项、国家重点研发计划、国家自然科学基金等20余项课题资助；做为PI主持创新药早期临床试验100余项；获得国家药品监督管理局药物批件、欧盟药监局药物研究计划PIP批件10余项；做为第一完成人，获得教育部科技进步二等奖1项、山东省教学成果二等奖1项。参与获得北京市科技进步二等奖1项、中华医学科技奖医学科学技术二等奖1项。荣获欧洲临床药理与治疗学协会青年研究员奖、欧洲围产期与儿科药理协会青年研究员奖、中国研究型医院学会研究型人才、山东省泰山学者特聘专家、山东大学杰出中青年学者等荣誉称号。

1. Leroux S, Turner MA, Guellec CB, Hill H, van den Anker JN, Kearns GL, Jacqz-Aigrain E, Zhao W*; TINN (Treat Infections in NeoNates) and GRiP (Global Research in Paediatrics) Consortiums. “Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design”. Clin Pharmacokinet. 2015 2. Zhao W*, Zhang D, Storme T, Baruchel A, Declèves X, Jacqz-Aigrain E.“Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease”. Br J Clin Pharmacol 2015;80(5):1197-207. 3. Zhao W*, Le Guellec C, Benjamin DK Jr, Hope WW, Bourgeois T, Watt KM, van den Anker JN, Matrot B, Saxen H, Hoppu K, Manzoni P, Jacqz-Aigrain E, on behalf of the TINN (Treat Infections in NeoNates) and GRiP (Global Research in Paediatrics) consortiums. “First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole?” Clin Pharmacokinet 2014; 53(11):1005-1018. 4. Zhang B, Fila M, Fakhoury M, Baudouin V, Deschênes G, Jacqz-Aigrain E, Zhao W.* “Pharmacokinetics and dosage individualization of ganciclovir and valganciclovir in an infant with nephrotic syndrome associated with cytomegalovirus infection”. J Antimicrob Chemother 2014; 69(4):1150-1151. 5. Zhao W, Zhang D, Fakhoury M, Fahd M, Duquesne F, Storme T, Baruchel A, Jacqz-Aigrain E. “Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease”. Antimicrob Agents Chemother 2014; 58(6):3191-3199. 6. Zhao W, Hill H, Le Guellec C, Neal T, Mahoney S, Paulus S, Castellan C, Kassai B, van den Anker JN, Kearns GL, Turner MA, Jacqz-Aigrain E, on behalf of the TINN (Treat Infections in NeoNates) consortium. “Population pharmacokinetics of ciprofloxacin in neonates and young infants less than 3 months of age”. Antimicrob Agents Chemother 2014; 58(11):6572-6580. 7. Zhao W, Biran V, Jacqz-Aigrain E. “Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates” Clin Pharmacokinet 2013; 52(12):1127-1134. 8. Zhao W,Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, Holford N, Kimura T, Lo YL, Peris JE, Thomson A, van den Anker JN, Fakhoury M, Jacqz-Aigrain E. “External evaluation of population pharmacokinetic models of vancomycin in neonates: The transferability of published models to different clinical settings". Br J Clin Pharmacol 2013; 75(4):1068-1080. 9. Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-Aigrain E. “Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring”. Arch Dis Child 2013; 98(6):449-453. 10. Zhao W, Piana C, Danhof M, Burger D, Della Pasqua O, Jacqz-Aigrain E. Population pharmacokinetics of abacavir in infants, toddlers and children. Br J Clin Pharmacol. 2013;75(6):1525-35.